Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8000377 | 0.83 | SMPD1 (0.39) | BACE1IRAK4HDAC6GAADPP4 | |
| SCHEMBL8002161 | 0.82 | KDM4E (0.49) | BACE1IRAK4GAADPP4ADORA2A | |
| SCHEMBL8005374 | 0.79 | IRAK4 (0.37) | BACE1IRAK4GAADPP4ADORA2A | |
| SCHEMBL6119983 | 0.79 | GAA (0.39) | BACE1HDAC4HDAC6GAADPP4 | |
| SCHEMBL3315954 | 0.79 | MAPT (0.41) | BACE1IRAK4HDAC4KDM4EMAPT | |
| SCHEMBL1326724 | 0.76 | — | — | |
| SCHEMBL1829391 | 0.76 | — | — | |
| SCHEMBL21547848 | 0.75 | NPSR1 (0.43) | IRAK4DPP4KDM4EMAPTDPP8 | |
| SCHEMBL24408849 | 0.75 | PLK1 (0.35) | PLK1HDAC4HDAC6GAAADORA2A | |
| SCHEMBL12321703 | 0.75 | PIK3CG (0.41) | PLK1HDAC4HDAC6GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748412-B2 | Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators | ARGUSINA BIOSCIENCE INC. (KY) | 2014-06-10 | — | — | US | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-1847532-B1 | IGF-1R INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PLK1 1651/4885BACE1 3771/4885IRAK4 2115/4885 |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | PLK1 1955/4885BACE1 1107/4885IRAK4 981/4885 |
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | PLK1 3659/4885BACE1 1864/4885IRAK4 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.